Sequenom Laboratories
The only results that matter are accurate ones.

Sequenom laboratories makes LDTs

Sequenom Laboratories, a wholly owned subsidiary of Sequenom, Inc., is a CAP-accredited and CLIA-certified molecular diagnostics laboratory, dedicated to the development and commercialization of laboratory-developed tests (LDTs) for prenatal diseases and conditions. Sequenom Laboratories holds or has access to intellectual property for noninvasive prenatal testing using circulating cell-free fetal nucleic acids.

logo_explore-lab-(1).png

 

Our test menu

MaterniT21® PLUS noninvasive prenatal test
Clearly revolutionary.

The MaterniT21 PLUS test was the first commercial noninvasive prenatal test (NIPT) of its kind for the detection of a chromosomal anomaly known as trisomy 21, the most common cause of Down syndrome. Based on the pioneering work of Sequenom’s advisor and collaborator, Professor Dennis Lo, the technology isolates and analyzes circulating cell-free fetal nucleic acid from a maternal blood sample.

The MaterniT21 PLUS LDT reports on trisomy 21, 18, 13, 16 and 22, sex chromosome aneuploidies, fetal sex and select microdeletions in single or multifetal gestations as early as 10 weeks in a pregnancy.

VisibiliT™ noninvasive prenatal test
Simply relevant for the most common fetal trisomies.

The VisibiliT noninvasive prenatal test (NIPT) is the first LDT of its kind utilizing common trisomy information (for trisomy 21 and 18) mirrored after serum screening content.

HerediT® UNIVERSAL carrier screening test
Reveal the unknown.


The HerediT UNIVERSAL carrier screening LDT is a comprehensive, customizable expanded carrier test that screens for >250 diseases and >2,000 disease-causing mutations.

HerediT® CF carrier screening test
Replacing guesswork with science.


The HerediT CF carrier screening LDT analyzes the most clinically relevant mutations and variants related to cystic fibrosis.

SensiGene® Fetal RHD genotyping test
Early detection means better management.

The SensiGene Fetal RHD genotyping LDT is the only noninvasive prenatal test of its kind that detects fetal RHD genotype in RhD-sensitized mothers.

NextView™ tests for prenatal diagnostic testing
Diagnostic confirmation that complements NIPT.

The NextView LDTs provide a high-resolution, genome-wide microarray assessment of the patient sample from a chorionic villus sampling (CVS) or amniocentesis specimen.